Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mepenzolate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 12/20 | 1.00 |
| ▸ | CHRM1 known ✓ | P11229 | 4/20 | 0.77 |
| ▸ | CHRM2 | P08172 | 11/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.97 |
| ▸ | HRH1 | P35367 | 3/20 | 0.77 |
| ▸ | RAB9A | P51151 | 1/20 | 0.76 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.62 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.62 |
| ▸ | HTR2B | P41595 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mepenzolate SCHEMBL17071946 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2KCNH2CYP2D6LMNA | |
| Mepenzolate SCHEMBL44191 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2KCNH2CYP2D6LMNA | |
| Mepenzolate SCHEMBL99030 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2KCNH2CYP2D6LMNA | |
| Mepenzolate SCHEMBL17008166 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2KCNH2CYP2D6LMNA | |
| Mepenzolate SCHEMBL15575981 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2KCNH2CYP2D6LMNA | |
| Mepenzolate SCHEMBL15575855 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2KCNH2CYP2D6LMNA | |
| Mepenzolate SCHEMBL147471 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2KCNH2CYP2D6LMNA | |
| Mepenzolate SCHEMBL15865414 | 0.97 | CHRM3 (0.97) | CHRM3CHRM2KCNH2CYP2D6LMNA | |
| Mepenzolate SCHEMBL9441937 | 0.97 | CHRM3 (0.97) | CHRM3CHRM2KCNH2CYP2D6LMNA | |
| Mepenzolate SCHEMBL3635487 | 0.97 | CHRM3 (0.95) | CHRM3CHRM2KCNH2CYP2D6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3863708-B1 | MIXED IONIC CONDUCTORS AND CORRESPONDING DEVICES, SYSTEMS AND METHODS OF MAKING | BATTELLE MEMORIAL INSTITUTE (US) | 2024-09-11 | — | — | EP | claimed |
| CN-117177741-A | Combination of norepinephrine reuptake inhibitors and cannabinoids for the treatment of sleep apnea | 爱普宁公司(特拉华) | 2023-12-05 | — | — | CN | disclosed |
| US-20170334851-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2017-11-23 | — | — | US | disclosed |
| US-20170334851-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2017-11-23 | — | — | US | disclosed |
| US-20170183305-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2017-06-29 | — | — | US | disclosed |
| US-20170183305-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2017-06-29 | — | — | US | disclosed |
| WO-2015181837-A2 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2015-12-03 | — | — | WO | disclosed |
| US-20100130544-A1 | USE OF PARASYMPATHOLYTIC SUBSTANCES TO ENHANCE AND ACCELERATE STEM CELL DIFFERENTIATION, RELATED METHODS AND COMPOSITIONS | UNIVERSITA' DEGLI STUDI DI TORINO (IT) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334851-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | FNTB, PGGT1B, GGPS1 | CHRM3 2635/4885CHRM1 2219/4885CHRM2 2458/4885 |
| US-20170183305-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | FNTB, PGGT1B, GGPS1 | CHRM3 2635/4885CHRM1 2219/4885CHRM2 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.